Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HINT1 | P49773 | 4/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | KRAS | P01116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26211115 | 0.92 | NT5E (0.54) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL26622869 | 0.92 | HINT1 (0.56) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL17469466 | 0.89 | AHCY (0.64) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL16113892 | 0.89 | AHCY (0.64) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL13833306 | 0.89 | AHCY (0.64) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL16113889 | 0.89 | AHCY (0.64) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL17439986 | 0.89 | AHCY (0.64) | NT5EHPGDHINT1TGM2AHCY | |
| SCHEMBL26207729 | 0.88 | NT5E (0.63) | NT5EHINT1TGM2KRAS | |
| SCHEMBL17198349 | 0.88 | HPGD (0.64) | NT5EHPGDHINT1TGM2GSK3A | |
| SCHEMBL20248685 | 0.88 | HPGD (0.64) | NT5EHPGDHINT1TGM2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504970-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | New England Biolabs, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12173368-B2 | Compositions and analysis of dephosphorylated oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240301485-A1 | Compositions and Analysis of Dephosphorylated Oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023197015-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | NEW ENGLAND BIOLABS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230287489-A1 | Compositions and Analysis of Dephosphorylated Oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | NT5E 1352/4885HPGD 4495/4885HINT1 1204/4885 |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | NT5E 803/4885HPGD 3611/4885HINT1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.